Low base may push CPI inflation to a 4-month high of 5
时间:2024-06-26 06:32:53 阅读(143)
India’s retail inflation based on the Consumer Price Index (CPI) likely rose to a four-month high of 5.9% in December. This is believed to be due to the statistical effect of a low base, as sequentially price pressures have eased, according to an FE poll of 20 economists. The estimates range from 5.5% to 6.4%.
In November CPI inflation was at 5.55% and in December 2022, it was at 5.72%. At the projected 5.9%, the overall CPI index would be down 0.1% month-on-month in December.
Prices of key food items were down on a month-on-month basis in December. Onion prices were lower by 13.6% on month and potato by 3.8%. Tomato prices too were down by 2.8% in December.
Prices of wheat and pulses, on the other hand, remained flat during the month, while that of rice was up marginally by 0.8%. Onion prices that rose sharply in November have cooled off now, mainly on account of the government’s efforts to curb price pressures by extending the ban on the commodity’s exports till March.
Headline inflation has largely been guided by extreme volatility in food prices since July. However, December seems to be the month when food prices have more or less been in control; and would not starkly add to the headline print.
CMIE, nevertheless, feels that a low base would push food inflation to 10.60% in December from 8.70% in November. It projects vegetable inflation to have skyrocketed to 34% in December 17.70% in the previous month.
On core inflation – most economists feel that it may come in at slightly below 4% in December, primarily due to a high base effect. In December 2022, core inflation was at 6.1%.
“Retracement in global energy prices (crude oil, coal, natural gas) is helping ease input costs for firms; and despite resilient domestic demand, demand-pull pressures are not visible in core inflation components,” said Barclays, which has pegged core inflation to print 3.99% in December.
ICICI Securities Primary Dealership has projected core inflation at 4% and CMIE at 3.95%.
猜你喜欢
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.
- Markets end in positive zone after volatile session; realty and banks shine even as IT and pharma struggle
- Bharatmala project to be subsumed in Vision 2047
- Bids invited for city-gas in J&K, Ladak and northeast
- Bitcoin spot market is still a little ‘weird,’ ProShares strategist says
- Boost for shipbuilders- Mazagon Dock zooms 4%; wins third order in 10 days
- Budget 2023- Googly on capital gains leaves experts stumped, HNIs sweat
- Black Friday for investors as Nifty, Sensex bleed; Covid, recession threats spook Dalal Street bulls
- Mahindra & Mahindra Financial Services Rating- Neutral; Loan recovery to feel the heat with RBI ban